People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Cerus brings in new blood: William Dawson joins firm Aug. 9 as chief financial officer. Previously, Dawson served as CFO at biopharmaceutical firm Dynavax Technologies Corp., where he spearheaded the creation and $61 mil. IPO of Dynavax Asia. Dawson replaces Gregory Schafer, who had been Cerus' CFO since 1999. Cerus recently inked a marketing and distribution agreement with BioOne Corp for Asian commercialization of its Intercept blood system for pathogen inactivation. The Concord, Calif.-based concern's efforts to bring Intercept to the U.S. market encountered delays when it chose to halt its Phase III trial for the red blood cell pathogen reduction program after two patients developed antibodies (1"The Gray Sheet" March 29, 2004, p. 14)...